Psyence Biomedical (Psyence Biomedical) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Psyence Biomedical's long-term debt to total assests ratio for the quarter that ended in Mar. 2023 was 0.00.

Psyence Biomedical's long-term debt to total assets ratio stayed the same from Mar. 2021 (0.00) to Mar. 2023 (0.00).

Psyence Biomedical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Psyence Biomedical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical LT-Debt-to-Total-Asset Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
LT-Debt-to-Total-Asset	-	-	-

Psyence Biomedical LT-Debt-to-Total-Asset Calculation

Psyence Biomedical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	0	/	1.573
	=

Psyence Biomedical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (Q: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2023 )	/	Total Assets (Q: Mar. 2023 )
	=	0	/	1.573
	=

Psyence Biomedical (NAS:PBM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Psyence Biomedical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024